Protagonist Therapeutics (PTGX) Capital Expenditures (2015 - 2026)

Protagonist Therapeutics has reported Capital Expenditures for 12 years, with the latest figure at $110000.0 in Q1 2026.

• Quarterly Capital Expenditures fell 79.82% year-over-year to $110000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.2 million (down 30.34% YoY) and the FY2025 annual result came in at $1.6 million, up 17.34% from the prior year.
• Capital Expenditures declined to $110000.0 in Q1 2026 per PTGX's latest filing, from $1.6 million in the prior quarter.
• Over five years, Capital Expenditures peaked at $1.6 million in Q4 2025 and troughed at -$502000.0 in Q3 2022.
• A 5-year average of $216647.1 and a median of $176000.0 in 2023 frame the typical range for Capital Expenditures.
• The sharpest annual moves came in 2024 and 2025: Capital Expenditures jumped 2320.0% in 2024, then tumbled 1439.39% in 2025.
• Over 5 years, Capital Expenditures stood at -$42000.0 in 2022, then jumped by 145.24% to $19000.0 in 2023, then jumped by 1531.58% to $310000.0 in 2024, then jumped by 410.32% to $1.6 million in 2025, then tumbled by 93.05% to $110000.0 in 2026.
• According to Business Quant data, Capital Expenditures over the past three periods registered $110000.0, $1.6 million, and -$95000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.